Source: Annals of hematology. Unidade: FM
Subjects: FÁRMACOS IMUNOSSUPRESSORES, SOBREVIDA, MORTALIDADE
ABNT
KULASEKARARAJ, Austin et al. Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria. Annals of hematology, v. 104, n. 1, p. 81-94, 2025Tradução . . Disponível em: https://observatorio.fm.usp.br/handle/OPI/84810. Acesso em: 01 nov. 2025.APA
Kulasekararaj, A., Brodsky, R., Schrezenmeier, H., Griffin, M., Roeth, A., Piatek, C., et al. (2025). Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria. Annals of hematology, 104( 1), 81-94. doi:10.1007/s00277-025-06193-5NLM
Kulasekararaj A, Brodsky R, Schrezenmeier H, Griffin M, Roeth A, Piatek C, Ogawa M, Yu J, Patel AS, Gualandro SFM. Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria [Internet]. Annals of hematology. 2025 ; 104( 1): 81-94.[citado 2025 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/84810Vancouver
Kulasekararaj A, Brodsky R, Schrezenmeier H, Griffin M, Roeth A, Piatek C, Ogawa M, Yu J, Patel AS, Gualandro SFM. Ravulizumab demonstrates long-term efficacy, safety and favorable patient survival in patients with paroxysmal nocturnal hemoglobinuria [Internet]. Annals of hematology. 2025 ; 104( 1): 81-94.[citado 2025 nov. 01 ] Available from: https://observatorio.fm.usp.br/handle/OPI/84810
